FeesSafety
Pluang+

MPC Oceanic Group to acquire 41% stake in Marlow Navigation for $126M, expanding ship management services.

Company Fundamentals
04 Nov 2026, 16:00 WIB
GlobeNewsWire
View Source
Bullish
MPC Oceanic Group to acquire 41% stake in Marlow Navigation for $126M, expanding ship management services.

MPC Oceanic Group, majority-owned by Castor Maritime, agreed to buy a 41% stake in Marlow Navigation, a leading ship management company, for about $126 million. The deal includes $97 million in cash and $29 million in new shares, with Marlow shareholders gaining about 9% ownership in MPC Oceanic. The acquisition, expected to complete in early 2027 pending regulatory approvals, strengthens MPC Oceanic's position in crew and technical ship management, serving over 1,150 vessels globally. Financing will be partly from cash and debt, and Marlow's shareholders may join MPC Oceanic's supervisory board.

Castor Maritime's acquisition agreement with MPC Oceanic Group for a 41% stake in Marlow Navigation is reported here with Pluang's Industrials sector market data as context. For readers following Industrials, as of Nov 04, 2026 20:11 WIB, 72 of 136 priced US stocks rose while 57 fell. Notable movers include VRT at USD 220.00 with a -6.77% change, POWL at USD 152.83 down -6.43%, and GEV at USD 861.14 down -6.21%, with POWL showing 100% buy activity on Pluang.

More News

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...

Market News
Bearish
25 minutes ago
Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...

Company Fundamentals
Bullish
25 minutes ago
ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...

Market News
Bullish
25 minutes ago
New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...

Others
Bullish
25 minutes ago
Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...

Market News
Bullish
25 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App